Clinical Trial Update: Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol Z1I study evaluating AZD1775 (adavosertib) as a targeted treatment for cancers with BRCA genetic changes. The trial is currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Lymphoma
• Malignant Solid Tumor
• Multiple Myeloma

Drugs mentioned

• AZD1775 (Adavosertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING